G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 102 filers reported holding G1 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,106,167 | +729.2% | 1,362,354 | +805.6% | 0.03% | +650.0% |
| Q2 2023 | $374,588 | -53.5% | 150,437 | -50.0% | 0.00% | -63.6% |
| Q1 2023 | $806,342 | -85.6% | 300,874 | -70.8% | 0.01% | -85.3% |
| Q4 2022 | $5,587,291 | +61.6% | 1,028,967 | +271.6% | 0.08% | +56.2% |
| Q3 2022 | $3,458,000 | -61.0% | 276,900 | -84.6% | 0.05% | -65.0% |
| Q2 2022 | $8,878,000 | – | 1,797,182 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |